CRL
Charles River Laboratories
310.80$
+7.1%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.0% | 21.8% | 12.8% | 18.9% | 24.9% | 15.9% | 17.4% | 19.8% | 21.3% | 14.8% | 4.1% | 17.9% | 14.6% | |
| 7.7% | 7.9% | 8.4% | 8.4% | 8.7% | 10.2% | 12.2% | 11.6% | 8.5% | 7.9% | 6.7% | 6.7% | 7.4% | |
| 2.2% | 1.9% | 1.7% | 1.6% | 1.9% | 1.7% | 1.3% | 1.7% | 2.3% | 1.8% | 2.2% | 2.0% | 2.1% | |
| 3.6% | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.2% | 3.8% | -4.8% | -1.1% | 7.1% | -4.2% | 0.1% | 1.1% | -0.5% | 0.7% | -10.7% | 0.3% | -2.5% | |
| 6.4% | 7.7% | 7.8% | 3.8% | 3.8% | 7.5% | 6.0% | 3.4% | 3.5% | 8.9% | 5.6% | 3.1% | 5.3% | |
| -7.7% | -23.5% | -8.5% | -6.0% | -2.1% | -7.6% | -4.6% | -3.6% | -3.4% | -7.4% | -41.0% | 2.8% | -12.2% | |
| 0.4% | 0.6% | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | -0.9% | -0.9% | -10.0% | 0.0% | -35.9% | -0.7% | 0.0% | 0.0% | -20.9% | -11.5% | -8.1% | |
| -15.8% | – | – | – | -9.3% | -7.2% | 27.1% | -18.5% | -14.6% | -5.1% | 55.9% | -3.7% | 8.0% | |
| -15.9% | 12.2% | 1.8% | -27.9% | -20.6% | -7.6% | -10.7% | -22.0% | -15.2% | -5.2% | 34.9% | -16.4% | -0.5% | |
| -4.2% | 11.7% | 5.3% | -15.4% | 3.0% | -0.6% | 2.7% | -4.6% | 2.4% | 0.7% | -1.8% | 4.2% | 1.4% | |
| 13.6% | 14.1% | 5.0% | 15.0% | 21.1% | 8.4% | 11.4% | 16.4% | 17.7% | 5.9% | -1.5% | 14.8% | 9.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.